Differential Mutation Detection Capability Through Capture-Based Targeted Sequencing in Plasma Samples in Hepatocellular Carcinoma.
ctDNA
driver genes
hepatocellular carcinoma
liquid biopsy
targeted next-generation sequencing
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
08
2020
accepted:
09
04
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
epublish
Résumé
Circulating tumor DNA (ctDNA) is a promising biomarker for accurate monitoring and less invasive assessment of tumor burden and treatment response. Here, targeted next-generation sequencing (NGS) with a designed gene panel of 176 cancer-relevant genes was used to assess mutations in 90 ctDNA samples from 90 patients with multiple types of liver disease and 10 healthy donor samples for control. Using our ctDNA detection panel, we identified mutations in 98.89% (89/90) of patient plasma biopsy samples, and 19 coding variants located in 10 cancer-related genes [
Identifiants
pubmed: 33996539
doi: 10.3389/fonc.2021.596789
pmc: PMC8120297
doi:
Types de publication
Journal Article
Langues
eng
Pagination
596789Informations de copyright
Copyright © 2021 Gao, Xi, Yu, Xu, Wu and Huang.
Déclaration de conflit d'intérêts
HX was employed by the company Chongqing Precision Biotech Co., Ltd. Chongqing. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oncotarget. 2015 May 20;6(14):12809-21
pubmed: 25980577
J Intern Med. 2014 Jul;276(1):41-51
pubmed: 24661605
Dev Cell. 2009 Jul;17(1):9-26
pubmed: 19619488
Int J Cancer. 2014 Nov 1;135(9):2215-22
pubmed: 24659028
Transl Oncol. 2013 Jun 01;6(3):319-28
pubmed: 23730412
Expert Rev Anticancer Ther. 2012 Aug;12(8):1021-32
pubmed: 23030222
Gastroenterology. 2007 Jun;132(7):2557-76
pubmed: 17570226
BMC Bioinformatics. 2013;14 Suppl 2:S2
pubmed: 23368785
Hepatol Int. 2016 Jan;10(1):1-98
pubmed: 26563120
J Clin Oncol. 2010 Feb 10;28(5):744-52
pubmed: 20038723
Nat Genet. 2012 May 06;44(6):694-8
pubmed: 22561517
Cancer Discov. 2014 Jun;4(6):650-61
pubmed: 24801577
Nat Genet. 2011 Aug 07;43(9):828-9
pubmed: 21822264
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Cancer Discov. 2016 May;6(5):479-91
pubmed: 26969689
J Clin Oncol. 2011 Nov 1;29(31):4113-20
pubmed: 21969500
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Cancer Res. 2009 Sep 15;69(18):7385-92
pubmed: 19723656
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Nat Med. 2012 Feb 12;18(3):382-4
pubmed: 22327622
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32217756
Bioinformatics. 2014 Dec 1;30(23):3390-3
pubmed: 25143292
Gastroenterology. 2015 Oct;149(5):1226-1239.e4
pubmed: 26099527
Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50
pubmed: 20952405
Nat Med. 2014 May;20(5):548-54
pubmed: 24705333
Sci Transl Med. 2014 Feb 19;6(224):224ra24
pubmed: 24553385
Expert Opin Biol Ther. 2002 Jan;2(1):3-24
pubmed: 11772336
Annu Rev Genomics Hum Genet. 2012;13:171-205
pubmed: 22703171
Nat Genet. 2015 May;47(5):505-511
pubmed: 25822088
Sci Rep. 2013;3:2623
pubmed: 24022007
Blood. 2003 Mar 15;101(6):2377-80
pubmed: 12424198
NPJ Genom Med. 2020 Jan 14;5:33
pubmed: 32821429
Front Oncol. 2020 Feb 12;10:142
pubmed: 32117779
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422
Mol Cancer Ther. 2015 Jun;14(6):1488-94
pubmed: 25852059
J Clin Oncol. 2011 Jul 20;29(21):2866-74
pubmed: 21670455